P-57 An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18)

Abstract

BRAF inhibitor combination therapy became the standard of care for BRAF -mutated metastatic colorectal cancer (mCRC) based on the BEACON CRC trial, which showed a survival benefit of the three-drug combination regimen with BRAF and MEK inhibitors plus anti-EGFR antibody as well as the two-drug combination regimen with BRAF inhibitor and anti-EGFR antibody over standard chemotherapy. The two-drug combination regimen is approved in Europe and the US, while both three- and two-drug combination regimens are approved in Japan.